Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $56.33.

Several research analysts recently issued reports on the company. Bank of America cut their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 19th. Finally, Scotiabank decreased their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider James William Burns sold 2,799 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $93,878.46. Following the sale, the insider directly owned 28,650 shares of the company’s stock, valued at approximately $960,921. This trade represents a 8.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $627,198.00. Following the completion of the sale, the chief executive officer owned 105,401 shares of the company’s stock, valued at $3,535,149.54. This trade represents a 15.07% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,363 shares of company stock worth $1,619,654. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after purchasing an additional 85,339 shares during the last quarter. Erste Asset Management GmbH grew its stake in shares of Agios Pharmaceuticals by 10.9% during the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company’s stock valued at $65,439,000 after buying an additional 220,000 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $49,290,000. Frazier Life Sciences Management L.P. raised its position in shares of Agios Pharmaceuticals by 2.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock worth $35,152,000 after buying an additional 25,600 shares during the period. Finally, Deutsche Bank AG raised its position in shares of Agios Pharmaceuticals by 39.7% in the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company’s stock worth $30,732,000 after buying an additional 265,637 shares during the period.

Agios Pharmaceuticals Stock Down 7.0%

Agios Pharmaceuticals stock opened at $37.20 on Thursday. The firm has a market capitalization of $2.15 billion, a PE ratio of 3.31 and a beta of 0.73. Agios Pharmaceuticals has a 52 week low of $23.42 and a 52 week high of $62.58. The firm’s 50-day simple moving average is $35.13 and its 200 day simple moving average is $32.47.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The company had revenue of $8.73 million during the quarter, compared to analysts’ expectations of $9.86 million. On average, research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.